Switch theme
Sign up to access all valuation multiples
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
2000
767
LTM Revenue $375M
LTM EBITDA $133M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anhui Anke Biotechnology has a last 12-month revenue of $375M and a last 12-month EBITDA of $133M.
In the most recent fiscal year, Anhui Anke Biotechnology achieved revenue of $349M and an EBITDA of $128M.
Anhui Anke Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anhui Anke Biotechnology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $395M | $349M | XXX | XXX | XXX |
| Gross Profit | $252M | $309M | XXX | XXX | XXX |
| Gross Margin | 64% | 89% | XXX | XXX | XXX |
| EBITDA | $141M | $128M | XXX | XXX | XXX |
| EBITDA Margin | 36% | 37% | XXX | XXX | XXX |
| Net Profit | $96.9M | $117M | XXX | XXX | XXX |
| Net Margin | 25% | 33% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Anhui Anke Biotechnology's stock price is CNY 8 (or $1).
Anhui Anke Biotechnology has current market cap of CNY 13.5B (or $1.9B), and EV of CNY 12.1B (or $1.7B).
See Anhui Anke Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.9B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Anhui Anke Biotechnology has market cap of $1.9B and EV of $1.7B.
Anhui Anke Biotechnology's trades at 4.5x LTM EV/Revenue multiple, and 12.6x LTM EBITDA.
Analysts estimate Anhui Anke Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Anhui Anke Biotechnology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | XXX | XXX |
| P/E | 19.1x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 21.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAnhui Anke Biotechnology's NTM/LTM revenue growth is 22%
Anhui Anke Biotechnology's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Anhui Anke Biotechnology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Anhui Anke Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Anhui Anke Biotechnology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 59% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 46% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anhui Anke Biotechnology acquired XXX companies to date.
Last acquisition by Anhui Anke Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Anhui Anke Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Anhui Anke Biotechnology founded? | Anhui Anke Biotechnology was founded in 2000. |
| Where is Anhui Anke Biotechnology headquartered? | Anhui Anke Biotechnology is headquartered in China. |
| How many employees does Anhui Anke Biotechnology have? | As of today, Anhui Anke Biotechnology has 767 employees. |
| Is Anhui Anke Biotechnology publicy listed? | Yes, Anhui Anke Biotechnology is a public company listed on SHE. |
| What is the stock symbol of Anhui Anke Biotechnology? | Anhui Anke Biotechnology trades under 300009 ticker. |
| When did Anhui Anke Biotechnology go public? | Anhui Anke Biotechnology went public in 2009. |
| Who are competitors of Anhui Anke Biotechnology? | Similar companies to Anhui Anke Biotechnology include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's current market cap is $1.9B |
| What is the current revenue of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's last 12-month revenue is $375M. |
| What is the current EBITDA of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's last 12-month EBITDA is $133M. |
| What is the current EV/Revenue multiple of Anhui Anke Biotechnology? | Current revenue multiple of Anhui Anke Biotechnology is 4.5x. |
| What is the current EV/EBITDA multiple of Anhui Anke Biotechnology? | Current EBITDA multiple of Anhui Anke Biotechnology is 12.6x. |
| What is the current revenue growth of Anhui Anke Biotechnology? | Anhui Anke Biotechnology revenue growth between 2023 and 2024 was -12%. |
| Is Anhui Anke Biotechnology profitable? | Yes, Anhui Anke Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
